Zanubrutinib in Waldenström Macroglobulinemia

被引：2

作者：

Song, Yuan-bin ^{[1
]}

Xu, Jing-bo ^{[2
]}

Gale, Robert Peter ^{[1
,3
]}

Liang, Yang ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat sen Univ, Affiliated Hosp 5, Dept Hematol, Zhuhai, Guangdong, Peoples R China

[3] Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Immunol & Inflammat, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 04期

关键词：

P-VALUE; IBRUTINIB; TRIAL;

D O I：

10.1200/JCO.23.01881

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3

共 10 条

[1] [Anonymous], 2018, Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry
[2] Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Dimopoulos, Meletios A.
Opat, Stephen
D'Sa, Shirley
Jurczak, Wojciech
Lee, Hui-Peng
Cull, Gavin
Owen, Roger G.
Marlton, Paula
Wahlin, Bjoern E.
Garcia-Sanz, Ramon
McCarthy, Helen
Mulligan, Stephen
Tedeschi, Alessandra
Castillo, Jorge J.
Czyz, Jaroslaw
de Larrea, Carlos Fernandez
Belada, David
Libby, Edward
Matous, Jeffrey
Motta, Marina
Siddiqi, Tanya
Tani, Monica
Trneny, Marek
Minnema, Monique C.
Buske, Christian
Leblond, Veronique
Treon, Steven P.
Trotman, Judith
Chan, Wai Y.
Schneider, Jingjing
Allewelt, Heather
Patel, Sheel
Cohen, Aileen
Tam, Constantine S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5099 - +
[3] ema.europa.eu, Brukinsa-epar-public-assessment-report
[4] What is the P-value anyway?
Gale, R. P.
Zhang, M-J
[J]. BONE MARROW TRANSPLANTATION, 2016, 51 (11) : 1439 - 1440
[5] What is the (p-) value of the P-value?
Gale, R. P.
Hochhaus, A.
Zhang, M-J
[J]. LEUKEMIA, 2016, 30 (10) : 1965 - 1967
[6] Disease control should be the goal of therapy for WM patients
Kastritis, Efstathios
Dimopoulos, Meletios A.
[J]. BLOOD ADVANCES, 2017, 1 (25) : 2483 - 2485
[7] The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses
Prasad, Vinay
Kim, Chul
Burotto, Mauricio
Vandross, Andrae
[J]. JAMA INTERNAL MEDICINE, 2015, 175 (08) : 1389 - 1398
[8] A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Tam, Constantine S.
Opat, Stephen
D'Sa, Shirley
Jurczak, Wojciech
Lee, Hui-Peng
Cull, Gavin
Owen, Roger G.
Marlton, Paula
Wahlin, Bjorn E.
Garcia Sanz, Ramon
McCarthy, Helen
Mulligan, Stephen
Tedeschi, Alessandra
Castillo, Jorge J.
Czyz, Jaroslaw
Fernandez de Larrea, Carlos
Belada, David
Libby, Edward
Matous, Jeffrey, V
Motta, Marina
Siddiqi, Tanya
Tani, Monica
Trneny, Marek
Minnema, Monique C.
Buske, Christian
Leblond, Veronique
Trotman, Judith
Chan, Wai Y.
Schneider, Jingjing
Ro, Sunhee
Cohen, Aileen
Huang, Jane
Dimopoulos, Meletios
[J]. BLOOD, 2020, 136 (18) : 2038 - 2050
[9] Treon S., 2019, Hematological Oncol, V37, P184, DOI DOI 10.1002/H0N.141_2629
[10] Treon S.P., Hematol Oncol, V37, P184, DOI [10.1002/hon.1412629, DOI 10.1002/HON.1412629]

← 1 →